Search
26/10/2023
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Kwatra, SG, Yosipovitch, G, Legat, FJ, Reich, A, Paul, C, Simon, D, Naldi, L, Lynde, C, De Bruin-Weller, MS, Nahm, WK, Sauder, M, Gharib, R, Barbarot, S, Szepietowski, JC, Conrad, C, Fleischer, A, Laquer, VT, Misery, L, Serra-Baldrich, E, Lapeere, H, Ahmad, F, Lopez, ZKJ, Piketty, C, Ständer, S. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(17)DOI:10.1056/NEJMoa2301333. PMID:37888917. IF:96.300(Q1/1D).
01/10/2023
The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R, Pozo T, Alfageme F, Díaz Ley B, Osorio GF, Chico R, Vilarrasa E, Silvente C, Ciudad Blanco C, Romaní J, Martorell A, Fernández P, Romero Ferreiro C, Molina Leyva A. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.. Actas Dermo-Sifiliograficas. 2023; 114(9)DOI:10.1016/j.ad.2023.06.018. PMID:37479135. IF:(Q/D).
14/09/2023
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Girolomoni, G, Savage, L, Gisondi, P, Svensson, A, Mahe, E, Augustin, M, Puig, L. Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review. Dermatology and Therapy. 2023; DOI:10.1007/s13555-023-01014. PMID:. IF:3.500(Q1/3D).
01/09/2023
Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Society of Dermatology and Venerology
Gonzalez-Cantero, A, Boehncke, WH, De Sutter, J, Zamorano, JL, Lambert, J, Puig, L. Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Society of Dermatology and Venerology. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(9)DOI:10.1111/jdv.19191. PMID:37259959. IF:8.500(Q1/1D).